Physician profile
Gary C Bernard
NPI 1720181910
$2,551.86
in general payments reported to CMS, 2019-2025
27 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $174 · 2021: $310 · 2022: $362 · 2023: $420 · 2024: $610 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,545.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $899.14 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Axsome Therapeutics, INC. | $318.96 | 2023-2025 | Symbravo, Sunosi |
| Pfizer INC. | $239.51 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $185.74 | 2019-2025 | Airsupra |
| Hikma Pharmaceuticals USA | $173.65 | 2019-2025 | Ryaltris, Mitigare, Kloxxado |
| Lilly USA, LLC | $115.00 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Idorsia Pharmaceuticals US INC | $72.60 | 2022-2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $67.94 | 2019-2025 | Austedo Xr, Austedo Xr |
| Corcept Therapeutics | $41.24 | 2023 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.84 | 2024 | Caplyta |
| Eyevance Pharmaceuticals LLC | $36.21 | 2021 | |
| Exact Sciences Corporation | $36.07 | 2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $35.48 | 2019-2020 | |
| Acella Pharmaceuticals, LLC | $35.44 | 2024-2025 | NP Thyroid 60 |
| Nabriva Therapeutics, Plc | $31.55 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $31.19 | 2021 | |
| Allergan, INC. | $26.94 | 2019-2020 | |
| Amgen INC. | $24.86 | 2019 | |
| Alexion Pharmaceuticals, INC. | $21.83 | 2024 | Strensiq |
| Genzyme Corporation | $20.65 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.88 | 2022 | |
| Phadia US INC. | $15.84 | 2024 | Immunocap |
| Azurity Pharmaceuticals, INC. | $15.59 | 2023 | Adthyza |
| Eisai INC. | $14.60 | 2020 | |
| Astellas Pharma US INC | $13.17 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $13.10 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Bernard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.